THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced the outcome of its Type C meeting which was held with the Food and Drug Administration (“FDA”) on October 15, 2007. The purpose of the meeting was to discuss clinical endpoints for future clinical trials of Repros’ drug, Androxal™, in the treatment of secondary hypogonadism.
